Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes - PubMed (original) (raw)
. 2008 May;294(5):E846-52.
doi: 10.1152/ajpendo.00030.2008. Epub 2008 Mar 11.
Affiliations
- PMID: 18334612
- DOI: 10.1152/ajpendo.00030.2008
Free article
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
Antonio Cervera et al. Am J Physiol Endocrinol Metab. 2008 May.
Free article
Abstract
We examined the contributions of insulin secretion, glucagon suppression, splanchnic and peripheral glucose metabolism, and delayed gastric emptying to the attenuation of postprandial hyperglycemia during intravenous exenatide administration. Twelve subjects with type 2 diabetes (3 F/9 M, 44 +/- 2 yr, BMI 34 +/- 4 kg/m2, Hb A(1c) 7.5 +/- 1.5%) participated in three meal-tolerance tests performed with double tracer technique (iv [3-3H]glucose and oral [1-14C]glucose): 1) iv saline (CON), 2) iv exenatide (EXE), and 3) iv exenatide plus glucagon (E+G). Acetaminophen was given with the mixed meal (75 g glucose, 25 g fat, 20 g protein) to monitor gastric emptying. Plasma glucose, insulin, glucagon, acetaminophen concentrations and glucose specific activities were measured for 6 h post meal. Post-meal hyperglycemia was markedly reduced (P < 0.01) in EXE (138 +/- 16 mg/dl) and in E+G (165 +/- 12) compared with CON (206 +/- 15). Baseline plasma glucagon ( approximately 90 pg/ml) decreased by approximately 20% to 73 +/- 4 pg/ml in EXE (P < 0.01) and was not different from CON in E+G (81 +/- 2). EGP was suppressed by exenatide [231 +/- 9 to 108 +/- 8 mg/min (54%) vs. 254 +/- 29 to189 +/- 27 mg/min (26%, P < 0.001, EXE vs. CON] and partially reversed by glucagon replacement [247 +/- 15 to 173 +/- 18 mg/min (31%)]. Oral glucose appearance was 39 +/- 4 g in CON vs. 23 +/- 6 g in EXE (P < 0.001) and 15 +/- 5 g in E+G, (P < 0.01 vs. CON). The glucose retained within the splanchnic bed increased from approximately 36g in CON to approximately 52g in EXE and to approximately 60g in E+G (P < 0.001 vs. CON). Acetaminophen((AUC)) was reduced by approximately 80% in EXE vs. CON (P < 0.01). We conclude that exenatide infusion attenuates postprandial hyperglycemia by decreasing EGP (by approximately 50%) and by slowing gastric emptying.
Similar articles
- Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M. Linnebjerg H, et al. Regul Pept. 2008 Nov 29;151(1-3):123-9. doi: 10.1016/j.regpep.2008.07.003. Epub 2008 Jul 16. Regul Pept. 2008. PMID: 18675854 Clinical Trial. - Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M. Henkel E, et al. Metabolism. 2005 Sep;54(9):1168-73. doi: 10.1016/j.metabol.2005.03.024. Metabolism. 2005. PMID: 16125528 - Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH. Schwartz SL, et al. Clin Ther. 2008 May;30(5):858-67. doi: 10.1016/j.clinthera.2008.05.004. Clin Ther. 2008. PMID: 18555933 Clinical Trial. - Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
Gallwitz B. Gallwitz B. Int J Clin Pract. 2006 Dec;60(12):1654-61. doi: 10.1111/j.1742-1241.2006.01196.x. Int J Clin Pract. 2006. PMID: 17109672 Review. - Exenatide: a novel approach for treatment of type 2 diabetes.
Mikhail N. Mikhail N. South Med J. 2006 Nov;99(11):1271-9. doi: 10.1097/01.smj.0000240730.86237.b6. South Med J. 2006. PMID: 17195423 Review.
Cited by
- Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study.
Ghazanfar H, Javed N, Qasim A, Sosa F, Altaf F, Khan S, Mahasamudram J, Jyala A, Kandhi SD, Shin D, Mantri N, Sun H, Hanumanthu S, Patel H, Makker J, Balar B, Dev A, Chilimuri S. Ghazanfar H, et al. World J Gastroenterol. 2024 Jul 14;30(26):3221-3228. doi: 10.3748/wjg.v30.i26.3221. World J Gastroenterol. 2024. PMID: 39086638 Free PMC article. - Potential role of IGF-1/GLP-1 signaling activation in intracerebral hemorrhage.
Siddiqui EM, Mehan S, Bhalla S, Shandilya A. Siddiqui EM, et al. Curr Res Neurobiol. 2022 Sep 10;3:100055. doi: 10.1016/j.crneur.2022.100055. eCollection 2022. Curr Res Neurobiol. 2022. PMID: 36685765 Free PMC article. Review. - Bolus Injection of Liraglutide Raises Plasma Glucose in Normal Rats by Activating Glucagon-like Peptide 1 Receptor in the Brain.
Hsu CC, Cheng JT, Hsu PH, Li Y, Cheng KC. Hsu CC, et al. Pharmaceuticals (Basel). 2022 Jul 21;15(7):904. doi: 10.3390/ph15070904. Pharmaceuticals (Basel). 2022. PMID: 35890201 Free PMC article. - Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
Alatrach M, Agyin C, Solis-Herrera C, Lavryneko O, Adams J, Gastaldelli A, Triplitt C, DeFronzo RA, Cersosimo E. Alatrach M, et al. Diabetes Care. 2022 Jun 2;45(6):1372-1380. doi: 10.2337/dc21-1798. Diabetes Care. 2022. PMID: 35235659 Free PMC article. - Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial.
Hamidi V, Riggs K, Zhu L, Bermudez Saint Andre K, Westby C, Coverdale S, Dursteler A, Wang H, Miller Iii C, Taegtmeyer H, Gutierrez AD. Hamidi V, et al. Metab Syndr Relat Disord. 2020 Jun;18(5):225-233. doi: 10.1089/met.2019.0102. Epub 2020 Mar 31. Metab Syndr Relat Disord. 2020. PMID: 32228379 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous